Latest News Archive
Please select Category, Year, and then Month to display items
16 April 2024
|
Story Anthony Mthembu
|
Photo Supplied
Melanie Ridgard celebrates receiving a Master of Business Administration (MBA) at the graduation ceremony held at the UFS Bloemfontein campus on 19 April 2024.
In the realm of self-development, few stories are as inspiring as that of Melanie Ridgard, the Interim Administration and Events Coordinator at the South African Research Chair in Industrial Development (SARChI-ID) at the University of Johannesburg (UJ). Ridgard’s forthcoming graduation with a Master in Business Administration (MBA) on 19 April 2024 from the University of the Free State (UFS) marks not only a personal triumph but also a testament to the transformative power of higher education.
Reflecting on her journey, Ridgard shares, “This moment signifies a culmination of rigorous studying, dedication and perseverance in mastering business fundamentals, leadership skills and strategic thinking.” Her pursuit of an MBA stemmed from a pivotal moment in her career when she was promoted at the Centre for Teaching and Learning (CTL) at UFS. Tasked with leading a group of young people Ridgard recognised the need to augment her knowledge to effectively guide her colleagues. The MBA became her vehicle for professional growth, extending beyond a mere qualification to a profound transformation of her leadership capabilities.
“Attaining an MBA milestone represents a transformative experience that has shaped my thinking to make impactful contributions in any future landscape,” Ridgard explains. Her experience not only enhanced her strategic acumen but also deepened her understanding of organisational dynamics. She acknowledges the pivotal role played by the UFS Business School in nurturing her journey towards academic and personal success.
What to expect from Ridgard
Looking ahead, Ridgard’s commitment to continuous learning remains unwavering. Selected as one of five MBA students to address the 17th International Business Conference (IBC) in September 2024, she eagerly anticipates the opportunity to share insights on her work titled, “Next-Gen Integration: Navigating the Onboarding Maze for Gen Z in Today's Workplace.” Despite her current responsibilities at UJ, she harbors plans to pursue a PhD in the near future.
Amidst her ambitious pursuits, Ridgard remains grounded, prioritising the celebration of her MBA achievement. ‘’As everyone dreams about it, I just want to walk over that stage in a black gown and a hood on my head with my loved ones cheering me on,’’ she shared.
Ridgard’s journey serves as a beacon of inspiration, exemplifying the transformative potential of education and the enduring impact of determined leadership. Her story reminds us that true leadership is not merely about reaching milestones but also about empowering others and embracing continuous growth.
New research informs improved treatment of brain inflammation
2017-10-13
Dr Adepemi Ogundeji, researcher in the Department of Microbial,
Biochemical and Food Biotechnology at the
University of the Free State,and Dr Olihile Sebolai,
her study leader from the same department.
Photo: Charl Devenish
Microbiologist Dr Adepemi Ogundeji has uncovered a new use for an old medicine that can potentially save lives and money. Under the guidance of her study leader, Dr Olihile Sebolai, Dr Ogundeji set out to fight a fungal disease caused by Cryptococcus neoformans. Drs Ogundeji and Sebolai are from the University of the Free State Department of Microbial, Biochemical and Food Biotechnology.
Dr Ogundeji is passionate about education. “My aim will always be to transfer knowledge and skills in the microbiology field,” she said. “Dr Ogundeji’s study is celebrated in that it found a new purpose for existing medicines. An advantage of repositioning old medicines is by-passing clinical trials, which sometimes take 20 years, and the safety of such medicines is already known,” Dr Sebolai, explained.
Cryptococcus infections are difficult to control and often lead to brain inflammation. In layman’s terms: “Your brain is on fire”. People with HIV/Aids are especially vulnerable, surviving only about three months without treatment. Such patients may present with a Cryptococcus-emergent psychosis, and some with an out-of-control inflammatory condition when initiated on ARVs.
Dr Ogundeji found that the clinically recommended dosage of aspirin (anti-inflammatory medicine), and quetiapine (anti-psychotic medicine) is sufficient to control the infection. Her exceptional work was readily published in some of the foremost journals in her field, namely, Antimicrobial Agents and Chemotherapy and Frontiers in Microbiology